December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.7778 +0.0378 (+5.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2023 Financial, Corporate Report
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
  
Via Benzinga
News headline image
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 11, 2022 ↗
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
News headline image
VistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study ↗
 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss FY 2023 Q1 Financial Results
Via Investor Brand Network
News headline image
VistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
From VistaGen
Via Business Wire
News headline image
Vistagen Therapeutics Shares Are Falling Sharply: Here's Why ↗
Vistagen Therapeutics Inc (NASDAQ: VTGN) shares are trading lower by 7.57% to $0.16 Tuesday morning after Maxim Group downgraded the stock from Buy to Hold. What Else? 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday ↗
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday ↗
Gainers 
Via Benzinga
News headline image
Recap Of Friday's Biotech Catalysts - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Dow Dips More Than 200 Points; Crude Oil Moves Lower ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Friday. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
  
Via Benzinga
News headline image
Why Is Pagaya Technologies (PGY) Stock Soaring 94% Today? ↗
Pagaya Technologies (PGY) stock is rocketing higher on Friday despite a lack of news from the financial tech company today. 
Via InvestorPlace
News headline image
Nasdaq Drops Around 200 Points; Hanger Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 200 points on Friday. 
Via Benzinga
News headline image
This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares gained 93% to $10.32. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
News headline image
VistaGen Therapeutics (VTGN) Stock Plunges on Disappointing Clinical Data ↗
VistaGen Therapeutics (VTGN) stock is falling hard on Friday after the company reported poor results from a Phase 3 study. 
Via InvestorPlace
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for PH94B
Via Investor Brand Network
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday saw 37 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  On Friday, 137 stocks made new 52-week lows. 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at 2022 Concordia Americas Summit; CEO and US Surgeon General to Discuss Mental Health Crisis
Via Investor Brand Network
News headline image
VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at William Blair Biotech Focus Conference 2022
Via Investor Brand Network
News headline image
VistaGen to Participate at William Blair Biotech Focus Conference 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.